Inhibition of Enteral Enzymes by Enteroclysis with Nafamostat Mesilate Reduces Neutrophil Activation and Transfusion Requirements after Hemorrhagic Shock

Journal of Trauma - Injury, Infection and Critical Care

Volumn 56, Issue 3, 2004, Pages 501-511

  Doucet, Jay J ^a   Hoyt, David B ^a,d   Coimbra, Raul ^a   Schmid Schönbein, Geert W ^b   Junger, Wolfgang G ^a   Wolf, Paul L ^c   Loomis, William H ^e   Hugh, Tony E ^b   Deitch, Edwin A ^e   Hauser, Carl J ^e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UCSD MEDICAL CENTER   (United States)

^e NONE

Author keywords

Enteroclysis; Hemorrhagic shock; Nafamostat mesilate; Resuscitation; Serine protease activity

Indexed keywords

ENEMA; GOLYTELY; INTERLEUKIN 8; INTESTINE ENZYME; MYELOPEROXIDASE; NAFAMSTAT MESILATE; PROTEIN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TRYPSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BLOOD TRANSFUSION; CELL ACTIVATION; CELL ULTRASTRUCTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DUODENUM INTUBATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INACTIVATION; ENZYME INHIBITION; HEMORRHAGIC SHOCK; HISTOPATHOLOGY; INFLAMMATION; INTESTINE FLUID; INTESTINE INJURY; LAPAROTOMY; LEUKOCYTE ACTIVATION; LIVER INJURY; MALE; MEAN ARTERIAL PRESSURE; MULTIPLE ORGAN FAILURE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RESUSCITATION; SPECTROPHOTOMETRY; SWINE; TECHNIQUE;

EID: 11144356368     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TA.0000114536.98447.F7     Document Type: Article

References (17)

1. Deitch EA. Multiple organ failure: pathophysiology and potential future therapy. Ann Surg. 1992;216:117-134.
2. Moore EE, Moore FA, Franciose RJ, Kim FJ, Biffl WL, Banerjee A. The postischemic gut serves as a priming bed for circulating neutrophils that provoke multiple organ failure. J Trauma. 1994; 37:881-887.
3. Moore FA, Moore EE, Poggetti R, et al. Gut bacterial translocation via the portal vein: a clinical perspective with major torso trauma. J Trauma. 1991;31:629-636.
4. Upperman JS, Deitch EA, Guo W, Lu Q, Xu D. Post-hemorrhagic shock mesenteric lymph is cytotoxic to endothelial cells and activates neutrophils. Shock. 1998;10:407-414.
5. Montgomery A, Borgstrom A, Haglund U. Pancreatic proteases and intestinal mucosal injury after ischemia and reperfusion in the pig. Gastroenterology. 1992;102:216-222.
6. Mitsuoka H, Kistler EB, Schmid-Schonbein GW. Generation of in vivo activating factors in the ischemic intestine by pancreatic enzymes. Proc Natl Acad Sci USA. 2000;97:1772-1777.
7. Kistler EB, Lefer AM, Hugh TE, Schmid-Schonbein GW. Plasma activation during splanchnic arterial occlusion shock. Shock. 2000; 14:30-34.
8. Mitsuoka H, Kistler EB, Schmid-Schonbein GW. Protease inhibition in the intestinal lumen: attenuation of systemic inflammation and early indicators of multiple organ failure in shock. Shock. 2002; 17:205-209.
9. Deitch EA, Shi HP, Lu Q, Feketeova E, Xu DZ. Serine proteases are involved in the pathogenesis of trauma-hemorrhagic shock-induced gut and lung injury. Shock. 2003;19:452-456.
10. Kistler EB, Hugh TE, Schmid-Schonbein GW. The pancreas as a source of cardiovascular cell activating factors. Microcirculation. 2000;7:183-192.
11. Mitsuoka H, Schmid-Schonbein GW. Mechanisms for blockade of in vivo activator production in the ischemic intestine and multi-organ failure. Shock. 2000;14:522-527.
12. Waldo SW, Rosario HS, Penn AH, Schmid-Schonbein GW. Pancreatic digestive enzymes are potent generators of mediators for leukocyte activation and mortality. Shock. 2003;20:138-143.
13. Schmid-Schonbein GW, Kistler EB, Hugh TE. Mechanisms for cell activation and its consequences for biorheology and microcirculation: multi-organ failure in shock. Biorheology. 2001;38:185-201.
14. Kramp WJ, Schmid-Schönbein GW, Hoyt DB, Coimbra R, Hugh TE. Characterization of two classes of pancreatic shock factors: functional differences exhibited by hydrophilic and hydrophobic shock factors. Shock. 2003;20:356-362.
15. Aoyama T, Ino Y, Ozeki M, et al. Pharmacological studies of FUT-175, nafamostat mesilate: I - inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol. 1984;35:203-227.
16. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta. 1981;661:342-345.
17. Noguchi S, Nakatsuka M, Konishi H, Kamada Y, Chekir C, Kudo T. Nafamostat mesilate suppresses NF-kappaB activation and NO overproduction in LPS-treated macrophages. Int Immunopharmacol. 2003;3:1335-1344.